{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:50:50Z","timestamp":1770965450269,"version":"3.50.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40261-022-01178-y","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:03:52Z","timestamp":1657703032000},"page":"631-642","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends"],"prefix":"10.1007","volume":"42","author":[{"given":"Arnaldo","family":"Figueiredo","sequence":"first","affiliation":[]},{"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Maria Joaquina","family":"Maur\u00edcio","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Figueira","sequence":"additional","affiliation":[]},{"given":"Rodrigo","family":"Ramos","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Martins-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"1178_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0094-0143(02)00182-9","volume":"30","author":"B Kessler","year":"2003","unstructured":"Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin N Am. 2003;30:219\u201326. https:\/\/doi.org\/10.1016\/S0094-0143(02)00182-9.","journal-title":"Urol Clin N Am"},{"key":"1178_CR2","unstructured":"National Cancer Institute. SEER stat fact sheets: prostate cancer. 2021. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 23 Sept 2021."},{"key":"1178_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1178_CR4","unstructured":"Miranda AC, Mayer-da-Silva A, Gl\u00f3ria L, Brito C. Registo Oncol\u00f3gico Nacional de Todos os Tumores na Popula\u00e7\u00e3o Residente em Portugal, em 2018. 2021. https:\/\/ron.min-saude.pt\/media\/2196\/2021-0518_publica%C3%A7%C3%A3o-ron_2018.pdf. Accessed 10 Jan 2022."},{"key":"1178_CR5","first-page":"S3","volume":"9","author":"A Perlmutter","year":"2007","unstructured":"Perlmutter A, Mark A, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9:S3-8.","journal-title":"Rev Urol"},{"key":"1178_CR6","doi-asserted-by":"publisher","unstructured":"Sun M, Choueiri TK, Hamnvik O-PR, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy. JAMA Oncol. 2016;2:500. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4917.","DOI":"10.1001\/jamaoncol.2015.4917"},{"key":"1178_CR7","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0022-5347(17)41100-1","volume":"141","author":"DP Byar","year":"1989","unstructured":"Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group Studies. J Urol. 1989;141:1032\u20133. https:\/\/doi.org\/10.1016\/S0022-5347(17)41100-1.","journal-title":"J Urol"},{"key":"1178_CR8","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293\u20137.","journal-title":"Cancer Res"},{"key":"1178_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","volume":"140","author":"AA Shafi","year":"2013","unstructured":"Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013;140:223\u201338. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.07.003.","journal-title":"Pharmacol Ther"},{"key":"1178_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/RRU.S264722","volume":"13","author":"F Crowley","year":"2021","unstructured":"Crowley F, Sterpi M, Buckley C, et al. A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer. Res Rep Urol. 2021;13:457\u201372. https:\/\/doi.org\/10.2147\/RRU.S264722.","journal-title":"Res Rep Urol."},{"key":"1178_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12916-015-0457-6","volume":"13","author":"T Chandrasekar","year":"2015","unstructured":"Chandrasekar T, Yang JC, Gao AC, et al. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206. https:\/\/doi.org\/10.1186\/s12916-015-0457-6.","journal-title":"BMC Med"},{"key":"1178_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","volume":"67","author":"T Karantanos","year":"2015","unstructured":"Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67:470\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.049.","journal-title":"Eur Urol"},{"key":"1178_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.e16052","volume":"31","author":"A Liede","year":"2013","unstructured":"Liede A, Arellano J, Hechmati G, et al. International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). J Clin Oncol. 2013;31: e16052. https:\/\/doi.org\/10.1200\/jco.2013.31.15_suppl.e16052.","journal-title":"J Clin Oncol"},{"key":"1178_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","volume":"19","author":"E Schaeffer","year":"2021","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, et al. NCCN guidelines insights: prostate cancer, Version 1.2021. J Natl Compr Cancer Netw. 2021;19:134\u201343. https:\/\/doi.org\/10.6004\/jnccn.2021.0008.","journal-title":"J Natl Compr Cancer Netw."},{"key":"1178_CR15","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"1178_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","volume":"96","author":"DM Moreira","year":"2016","unstructured":"Moreira DM, Howard LE, Sourbeer KN, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171\u20136. https:\/\/doi.org\/10.1016\/j.urology.2016.06.011.","journal-title":"Urology"},{"key":"1178_CR17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/cncr.25762","volume":"117","author":"MR Smith","year":"2011","unstructured":"Smith MR, Cook R, Lee K-A, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011;117:2077\u201385. https:\/\/doi.org\/10.1002\/cncr.25762.","journal-title":"Cancer"},{"key":"1178_CR18","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918\u201325. https:\/\/doi.org\/10.1200\/JCO.2005.01.529.","journal-title":"J Clin Oncol"},{"key":"1178_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.urolonc.2014.03.024","volume":"32","author":"AR Metwalli","year":"2014","unstructured":"Metwalli AR, Rosner IL, Cullen J, et al. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol. 2014;32:761\u20138. https:\/\/doi.org\/10.1016\/j.urolonc.2014.03.024.","journal-title":"Urol Oncol"},{"key":"1178_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"key":"1178_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(14)71205-7.","journal-title":"Lancet Oncol"},{"key":"1178_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.urology.2013.10.026","volume":"83","author":"ED Crawford","year":"2014","unstructured":"Crawford ED, Stone NN, Yu EY, et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014;83:664\u20139. https:\/\/doi.org\/10.1016\/j.urology.2013.10.026.","journal-title":"Urology"},{"key":"1178_CR23","doi-asserted-by":"publisher","first-page":"17.e9","DOI":"10.1016\/j.urolonc.2014.09.010","volume":"33","author":"F Roghmann","year":"2015","unstructured":"Roghmann F, Antczak C, McKay RR, et al. The burden of skeletal-related events in patients with prostate cancer and bone metastasis. Urol Oncol Semin Orig Investig. 2015;33:17.e9-17.e18. https:\/\/doi.org\/10.1016\/j.urolonc.2014.09.010.","journal-title":"Urol Oncol Semin Orig Investig."},{"key":"1178_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/iju.13170","volume":"23","author":"S Tsuzuki","year":"2016","unstructured":"Tsuzuki S, Park SH, Eber MR, et al. Skeletal complications in cancer patients with bone metastases. Int J Urol. 2016;23:825\u201332. https:\/\/doi.org\/10.1111\/iju.13170.","journal-title":"Int J Urol"},{"key":"1178_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","volume":"23","author":"MS Broder","year":"2015","unstructured":"Broder MS, Gutierrez B, Cherepanov D, et al. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015;23:237\u201347. https:\/\/doi.org\/10.1007\/s00520-014-2437-3.","journal-title":"Support Care Cancer"},{"key":"1178_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/J.EUF.2016.09.008","volume":"4","author":"HM Westgeest","year":"2018","unstructured":"Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, et al. Differences in trial and real-world populations in the Dutch Castration-Resistant Prostate Cancer Registry. Eur Urol Focus. 2018;4:694\u2013701. https:\/\/doi.org\/10.1016\/J.EUF.2016.09.008.","journal-title":"Eur Urol Focus"},{"key":"1178_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387\u201395. https:\/\/doi.org\/10.1016\/j.crad.2007.05.022.","journal-title":"Clin Radiol"},{"key":"1178_CR28","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","volume":"43","author":"G Shen","year":"2014","unstructured":"Shen G, Deng H, Hu S, et al. Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skelet Radiol. 2014;43:1503\u201313. https:\/\/doi.org\/10.1007\/s00256-014-1903-9.","journal-title":"Skelet Radiol"},{"key":"1178_CR29","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68 Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374. https:\/\/doi.org\/10.2967\/jnumed.115.154153.","journal-title":"J Nucl Med"},{"key":"1178_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","volume":"56","author":"JJ Morigi","year":"2015","unstructured":"Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18 F-fluoromethylcholine versus 68 Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185\u201390. https:\/\/doi.org\/10.2967\/jnumed.115.160382.","journal-title":"J Nucl Med"},{"key":"1178_CR31","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2214\/AJR.11.8351","volume":"199","author":"F Mosavi","year":"2012","unstructured":"Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with 18 F-NaF PET\/CT for detection of bone metastases in patients with high-risk prostate carcinoma. Am J Roentgenol. 2012;199:1114\u201320. https:\/\/doi.org\/10.2214\/AJR.11.8351.","journal-title":"Am J Roentgenol"},{"key":"1178_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2013.04.019","volume":"64","author":"MH Umbehr","year":"2013","unstructured":"Umbehr MH, M\u00fcntener M, Hany T, et al. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET\/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. 2013;64:106\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2013.04.019.","journal-title":"Eur Urol"},{"key":"1178_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","volume":"73","author":"I Rauscher","year":"2018","unstructured":"Rauscher I, D\u00fcwel C, Haller B, et al. Efficacy, predictive factors, and prediction Nnmograms for 68 Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol. 2018;73:656\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.006.","journal-title":"Eur Urol"},{"key":"1178_CR34","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1200\/JCO.2018.36.15_suppl.5001","volume":"36","author":"W Fendler","year":"2018","unstructured":"Fendler W, Calais J, Gartmann J, et al. Accuracy of 68 Ga-PSMA11 PET\/CT on recurrent prostate cancer: preliminary results from a phase 2\/3 prospective trial. J Clin Oncol. 2018;36:5001. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.5001.","journal-title":"J Clin Oncol"},{"key":"1178_CR35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, et al. 68 Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688\u201397. https:\/\/doi.org\/10.1021\/bc200279b.","journal-title":"Bioconjug Chem"},{"key":"1178_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/bjc.1995.377","volume":"72","author":"J Leek","year":"1995","unstructured":"Leek J, Lench N, Maraj B, et al. Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer. 1995;72:583\u20138. https:\/\/doi.org\/10.1038\/bjc.1995.377.","journal-title":"Br J Cancer"},{"key":"1178_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol"},{"key":"1178_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41585-019-0268-1","volume":"17","author":"P Ost","year":"2020","unstructured":"Ost P. PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancer. Nat Rev Urol. 2020;17:133\u20134. https:\/\/doi.org\/10.1038\/s41585-019-0268-1.","journal-title":"Nat Rev Urol"},{"key":"1178_CR39","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00259-019-04581-4","volume":"47","author":"C Onal","year":"2020","unstructured":"Onal C, Guler OC, Torun N, et al. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47:632\u201341. https:\/\/doi.org\/10.1007\/s00259-019-04581-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1178_CR40","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:7448\u201354. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1050.","journal-title":"Clin Cancer Res"},{"key":"1178_CR41","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41598-020-58975-8","volume":"10","author":"A Fourquet","year":"2020","unstructured":"Fourquet A, Aveline C, Cussenot O, et al. 68Ga-PSMA-11 PET\/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients\u2019 disease management and adequacy of impact. Sci Rep. 2020;10:2104. https:\/\/doi.org\/10.1038\/s41598-020-58975-8.","journal-title":"Sci Rep"},{"key":"1178_CR42","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao SG, Chang SL, Erho N, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3:1663\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0751.","journal-title":"JAMA Oncol"},{"key":"1178_CR43","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1715546.","journal-title":"N Engl J Med"},{"key":"1178_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011.","journal-title":"Eur Urol"},{"key":"1178_CR45","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1800536.","journal-title":"N Engl J Med"},{"key":"1178_CR46","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2003892.","journal-title":"N Engl J Med"},{"key":"1178_CR47","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1815671.","journal-title":"N Engl J Med"},{"key":"1178_CR48","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"key":"1178_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469\u201376. https:\/\/doi.org\/10.1007\/s00259-020-04934-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1178_CR50","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.19.02757","volume":"38","author":"EJ Trabulsi","year":"2020","unstructured":"Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1963\u201396. https:\/\/doi.org\/10.1200\/JCO.19.02757.","journal-title":"J Clin Oncol"},{"key":"1178_CR51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","volume":"77","author":"S Gillessen","year":"2020","unstructured":"Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77:508\u201347. https:\/\/doi.org\/10.1016\/j.eururo.2020.01.012.","journal-title":"Eur Urol"},{"key":"1178_CR52","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.eururo.2006.10.062","volume":"51","author":"M Maffezzini","year":"2007","unstructured":"Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007;51:605\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2006.10.062.","journal-title":"Eur Urol"},{"key":"1178_CR53","first-page":"1035","volume":"15","author":"A Ruffion","year":"2005","unstructured":"Ruffion A, Rebillard X, Grima F. PSA doubling time and method of calculation. Prog Urol. 2005;15:1035\u201341.","journal-title":"Prog Urol"},{"key":"1178_CR54","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","volume":"75","author":"J Mateo","year":"2019","unstructured":"Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75:285\u201393. https:\/\/doi.org\/10.1016\/j.eururo.2018.07.035.","journal-title":"Eur Urol"},{"key":"1178_CR55","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","volume":"31","author":"MR Smith","year":"2013","unstructured":"Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800\u20136. https:\/\/doi.org\/10.1200\/JCO.2012.44.6716.","journal-title":"J Clin Oncol"},{"key":"1178_CR56","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1111\/bju.13856","volume":"120","author":"LE Howard","year":"2017","unstructured":"Howard LE, Moreira DM, De Hoedt A, et al. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017;120:E80\u20136. https:\/\/doi.org\/10.1111\/bju.13856.","journal-title":"BJU Int"},{"key":"1178_CR57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.bjmsu.2011.08.006","volume":"5","author":"AJ Vickers","year":"2012","unstructured":"Vickers AJ, Brewster SF. PSA velocity and doubling time in diagnosis and prognosis of prostate cancer. Br J Med Surg Urol. 2012;5:162\u20138. https:\/\/doi.org\/10.1016\/j.bjmsu.2011.08.006.","journal-title":"Br J Med Surg Urol."},{"key":"1178_CR58","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU guidelines: prostate cancer 2019. https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Accessed 7 Jul 2022."},{"key":"1178_CR59","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/ijms20081813","volume":"20","author":"I Kohaar","year":"2019","unstructured":"Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20:1813. https:\/\/doi.org\/10.3390\/ijms20081813.","journal-title":"Int J Mol Sci"},{"key":"1178_CR60","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fonc.2018.00397","volume":"8","author":"V Di Nunno","year":"2018","unstructured":"Di Nunno V, Gatto L, Santoni M, et al. Recent advances in liquid biopsy in patients with castration resistant prostate cancer. Front Oncol. 2018;8:397. https:\/\/doi.org\/10.3389\/fonc.2018.00397.","journal-title":"Front Oncol"},{"key":"1178_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4083183","volume":"2016","author":"Y Yokomizo","year":"2016","unstructured":"Yokomizo Y, Kawahara T, Miyoshi Y, et al. Efficacy of immediate switching from bicalutamide to flutamide as second-line combined androgen blockade. Biomed Res Int. 2016;2016:1\u20137. https:\/\/doi.org\/10.1155\/2016\/4083183.","journal-title":"Biomed Res Int"},{"key":"1178_CR62","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1200\/JCO.1997.15.8.2928","volume":"15","author":"HI Scher","year":"1997","unstructured":"Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol. 1997;15:2928\u201338. https:\/\/doi.org\/10.1200\/JCO.1997.15.8.2928.","journal-title":"J Clin Oncol"},{"key":"1178_CR63","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1200\/JCO.1993.11.8.1566","volume":"11","author":"HI Scher","year":"1993","unstructured":"Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol. 1993;11:1566\u201372. https:\/\/doi.org\/10.1200\/JCO.1993.11.8.1566.","journal-title":"J Clin Oncol"},{"key":"1178_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0022-5347(17)36163-3","volume":"149","author":"W Kevin Kelly","year":"1993","unstructured":"Kevin Kelly W, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149:607\u20139. https:\/\/doi.org\/10.1016\/S0022-5347(17)36163-3.","journal-title":"J Urol"},{"key":"1178_CR65","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1056\/NEJMp1805966","volume":"378","author":"JA Beaver","year":"2018","unstructured":"Beaver JA, Kluetz PG, Pazdur R. Metastasis-free survival: a new end point in prostate cancer trials. N Engl J Med. 2018;378:2458\u201360. https:\/\/doi.org\/10.1056\/NEJMp1805966.","journal-title":"N Engl J Med"},{"key":"1178_CR66","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","volume":"35","author":"W Xie","year":"2017","unstructured":"Xie W, Regan MM, Buyse M, et al. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol. 2017;35:3097\u2013104. https:\/\/doi.org\/10.1200\/JCO.2017.73.9987.","journal-title":"J Clin Oncol"},{"key":"1178_CR67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1200\/JCO.2021.39.6_suppl.197","volume":"39","author":"J Fallah","year":"2021","unstructured":"Fallah J, Zhang L, Weinstock C, et al. An FDA pooled analysis: characteristics and outcomes of patients with nonmetastatic castration-resistant prostate cancer, based on prior history of prostatectomy and\/or radiation therapy. J Clin Oncol. 2021;39:197. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.197.","journal-title":"J Clin Oncol"},{"key":"1178_CR68","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 4.2022). 2022.  https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed 10 Jan 2022."},{"key":"1178_CR69","first-page":"143","volume":"10","author":"D Pilon","year":"2017","unstructured":"Pilon D, Behl AS, Ellis LA, et al. Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy. Am Health Drug Benef. 2017;10:143\u201353.","journal-title":"Am Health Drug Benef."},{"key":"1178_CR70","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.urolonc.2020.03.022","volume":"38","author":"J Kumar","year":"2020","unstructured":"Kumar J, Jazayeri SB, Gautam S, et al. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis. Urol Oncol Semin Orig Investig. 2020;38:826\u201334. https:\/\/doi.org\/10.1016\/j.urolonc.2020.03.022.","journal-title":"Urol Oncol Semin Orig Investig."},{"key":"1178_CR71","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2015.01.026","volume":"68","author":"CS Higano","year":"2015","unstructured":"Higano CS, Beer TM, Taplin M-E, et al. Long-term safety and antitumor activity in the phase 1\u20132 study of enzalutamide in pre- and post-docetaxel castration-resistant prostate cancer. Eur Urol. 2015;68:795\u2013801. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.026.","journal-title":"Eur Urol"},{"key":"1178_CR72","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamaoncol.2017.3361","volume":"4","author":"S Slovin","year":"2018","unstructured":"Slovin S, Clark W, Carles J, et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure. JAMA Oncol. 2018;4:702. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3361.","journal-title":"JAMA Oncol"},{"key":"1178_CR73","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, et al. The rising tide of polypharmacy and drug\u2013drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med"},{"key":"1178_CR74","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","volume":"75","author":"GE Benoist","year":"2019","unstructured":"Benoist GE, van Oort IM, Burger DM, et al. The combination of enzalutamide and opioids: a painful pitfall? Eur Urol. 2019;75:351\u20132. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.011.","journal-title":"Eur Urol"},{"key":"1178_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84:122\u20139. https:\/\/doi.org\/10.1111\/bcp.13425.","journal-title":"Br J Clin Pharmacol"},{"key":"1178_CR76","unstructured":"Janssen Ortho LLC. Erleada (apalutamide) US prescribing information. 2018."},{"key":"1178_CR77","unstructured":"European Medicines Agency. Summary of product characteristics: Erleada. 2019."},{"key":"1178_CR78","unstructured":"European Medicines Agency. Summary of product characteristics: Xtandi. 2019."},{"key":"1178_CR79","unstructured":"Astellas Pharma US Inc. Xtandi (enzalutamide): US prescribing information. 2018."},{"key":"1178_CR80","unstructured":"European Medicines Agency. Erleada CHMP assessment report. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/erleada-epar-public-assessment-report_en.pdf. Accessed 10 Jan 2022."},{"key":"1178_CR81","unstructured":"European Medicines Agency. Xtandi CHMP assessment report. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-xtandi_en.pdf. Accessed 10 Jan 2022."},{"key":"1178_CR82","unstructured":"US Center for Drug Evaluation and Research. NDA\/BLA multidisciplinary review and evaluation NDA 210951 Erleada (apalutamide). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210951Orig1s000MultidisciplineR.pdf. Accessed 10 Jan 2022."},{"key":"1178_CR83","unstructured":"US Center for Drug Evaluation and Research. NDA\/BLA clinical pharmacology and biopharmaceutics review NDA 203415 Xtandi (enzalutamide). 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203415Orig1s000ClinPharmR.pdf. Accessed 10 Jan 2022."},{"key":"1178_CR84","doi-asserted-by":"publisher","unstructured":"Labrize F, Cany L, Massard C, et al. Enzalutamide and sleep apnea: an emerging central nervous system side-effect? Ann Oncol 2016;27:206. https:\/\/doi.org\/10.1093\/annonc\/mdv481.","DOI":"10.1093\/annonc\/mdv481"},{"key":"1178_CR85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18690","volume":"39","author":"S Appukkuttan","year":"2021","unstructured":"Appukkuttan S, Fu C, Du Y, et al. Prevalence of potential drug-drug interactions among nonmetastatic castration-resistant prostate cancer patients treated with apalutamide and enzalutamide. J Clin Oncol. 2021;39: e18690. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e18690.","journal-title":"J Clin Oncol"},{"key":"1178_CR86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1200\/JCO.2019.37.7_suppl.297","volume":"37","author":"C Zurth","year":"2019","unstructured":"Zurth C, Graudenz K, Denner K, et al. Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: results from clinical and in vitro studies. J Clin Oncol. 2019;37:297. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.297.","journal-title":"J Clin Oncol"},{"key":"1178_CR87","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494\u2013503. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3948.","journal-title":"Cancer Res"},{"key":"1178_CR88","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"A-M Moilanen","year":"2015","unstructured":"Moilanen A-M, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007. https:\/\/doi.org\/10.1038\/srep12007.","journal-title":"Sci Rep"},{"key":"1178_CR89","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"C Zurth","year":"2019","unstructured":"Zurth C, Koskinen M, Fricke R, et al. Drug\u2013drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44:747\u201359. https:\/\/doi.org\/10.1007\/s13318-019-00577-5.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1178_CR90","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.euf.2017.01.015","volume":"4","author":"ND Shore","year":"2018","unstructured":"Shore ND, Tammela TL, Massard C, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-na\u00efve and CYP17 inhibitor-na\u00efve patients: follow-up from the ARADES and ARAFOR Trials. Eur Urol Focus. 2018;4:547\u201353. https:\/\/doi.org\/10.1016\/j.euf.2017.01.015.","journal-title":"Eur Urol Focus"},{"key":"1178_CR91","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","volume":"9","author":"MA Rice","year":"2019","unstructured":"Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801. https:\/\/doi.org\/10.3389\/fonc.2019.00801.","journal-title":"Front Oncol"},{"key":"1178_CR92","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","volume":"14","author":"N Shore","year":"2019","unstructured":"Shore N, Zurth C, Fricke R, et al. Evaluation of clinically relevant drug\u2013drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019;14:527\u201339. https:\/\/doi.org\/10.1007\/s11523-019-00674-0.","journal-title":"Target Oncol"},{"key":"1178_CR93","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","volume":"25","author":"K Mori","year":"2020","unstructured":"Mori K, Mostafaei H, Pradere B, et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020;25:1892\u2013900. https:\/\/doi.org\/10.1007\/s10147-020-01777-9.","journal-title":"Int J Clin Oncol"},{"key":"1178_CR94","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2018.08.018","volume":"74","author":"LO Reis","year":"2018","unstructured":"Reis LO. Metastasis-free survival: progress or lowering the bar on nonmetastatic prostate cancer? Eur Urol. 2018;74:682\u20133. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.018.","journal-title":"Eur Urol"},{"key":"1178_CR95","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2020.38.6_suppl.318","volume":"38","author":"JZ Drago","year":"2020","unstructured":"Drago JZ, Kantoff PW, Stopsack KH. Adverse event profiles of apalutamide, enzalutamide, and darolutamide in SPARTAN, PROSPER, and ARAMIS: how confident are we about which drug is safest? J Clin Oncol. 2020;38:318. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.318.","journal-title":"J Clin Oncol"},{"key":"1178_CR96","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/14737140.2020.1772759","volume":"20","author":"R Gupta","year":"2020","unstructured":"Gupta R, Sheng IY, Barata PC, et al. Non-metastatic castration-resistant prostate cancer: current status and future directions. Expert Rev Anticancer Ther. 2020;20:513\u201322. https:\/\/doi.org\/10.1080\/14737140.2020.1772759.","journal-title":"Expert Rev Anticancer Ther"}],"updated-by":[{"DOI":"10.1007\/s40261-022-01212-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000}},{"DOI":"10.1007\/s40261-022-01239-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01178-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T09:17:57Z","timestamp":1674811077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1178"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01178-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-022-01239-2","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/s40261-022-01212-z","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"21 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-022-01212-z","URL":"https:\/\/doi.org\/10.1007\/s40261-022-01212-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-022-01239-2","URL":"https:\/\/doi.org\/10.1007\/s40261-022-01239-2","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bayer financially supported the medical writing company Prime Focus by providing writing assistance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AF received honoraria as a consultant\/speaker for Astellas, AstraZeneca, Bayer, BMS, Janssen, MSD, Novartis, Pfizer, Recordati, and Roche. LC received honoraria as a consultant\/speaker for Astellas, Bayer, BMS, Janssen, MSD, Roche, and Servier. MJM received honoraria as a consultant\/speaker for Bayer, BMS, Janssen, MSD, Ipsen, and Pfizer. RR received honoraria as a consultant\/speaker for Bayer, Janssen, and Pfizer. LF and CMS have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the review of the literature, article elaboration, and revision. All authors gave their final approval of the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}